What's new? Log in Free sign up

Sigilon Therapeutics (SGTX)

Company Profile

Company profile

Ticker

SGTX

Exchange

Website

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Sigilon Securities Corporation ...

IRS number

474005543

SGTX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Notice of effectiveness

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Prospectus update (post-effective amendment)

Completion of Acquisition or Disposition of Assets

Exchange delisting

Third party tender offer statement (amended)

Latest ownership filings

View all

Flagship Ventures Fund V, L.P.

Change in insider ownership

Douglas G. Cole

Stephen N. Oesterle

ROBERT R RUFFOLO

Matthew Paul Kowalsky

Financial summary

Financial statements Chart SGTX financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	20.91 mm	20.91 mm	20.91 mm	20.91 mm	20.91 mm	20.91 mm
Cash burn (monthly)	7.21 mm	1.25 mm	2.48 mm	2.57 mm	1.39 mm	2.73 mm
Cash used (since last report)	144.67 mm	25.08 mm	49.72 mm	51.55 mm	27.79 mm	54.78 mm
Cash remaining	-123.76 mm	-4.17 mm	-28.81 mm	-30.64 mm	-6.88 mm	-33.87 mm
Runway (months of cash)	-17.2	-3.3	-11.6	-11.9	-5.0	-12.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

SGTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	19	34	-44.1%
Opened positions	3	5	-40.0%
Closed positions	18	5	+260.0%
Increased positions	0	6	EXIT
Reduced positions	14	6	+133.3%

13F shares	Current	Prev Q	Change
Total value	27.03 bn	16.64 bn	+62.4%
Total shares	11.08 mm	29.07 mm	-61.9%
Total puts	14.00	700.00	-98.0%
Total calls	13.00 k	26.90 k	-51.7%
Total put/call ratio	0.0	0.0	-95.9%

Largest owners	Shares	Value	Change
Flagship Ventures Fund V	8.89 mm	$426.93 mm	0.0%
LLY Eli Lilly and	1.01 mm	$3.97 mm	-63.2%
Flagship Pioneering	797.72 k	$17.96 bn	-92.3%
Canada Pension Plan Investment Board	114.24 k	$2.57 bn	-92.3%
FMR	78.80 k	$1.77 bn	-92.5%
Harbourvest Partners	56.98 k	$1.28 bn	-92.3%
Yakira Capital Management	39.75 k	$894.68 mm	NEW
State Of Wisconsin Investment Board	39.20 k	$882.44 mm	-92.3%
Vanguard	23.14 k	$520.97 mm	-92.3%
CSS	13.29 k	$299.20 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Flagship Pioneering	797.72 k	-9.57 mm	-92.3%
LLY Eli Lilly and	1.01 mm	-1.74 mm	-63.2%
Canada Pension Plan Investment Board	114.24 k	-1.37 mm	-92.3%
BLK BlackRock	253.00	-1.05 mm	-100.0%
FMR	78.80 k	-975.80 k	-92.5%
Cercano Management	0.00	-884.92 k	EXIT
Harbourvest Partners	56.98 k	-683.76 k	-92.3%
State Of Wisconsin Investment Board	39.20 k	-470.43 k	-92.3%
Vanguard	23.14 k	-277.77 k	-92.3%
MS Morgan Stanley	6.42 k	-240.41 k	-97.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.